Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Join us on March 28, 2023 for this GEN webinar, where scientists from Codexis and Tune Therapeutics will highlight how engineered enzymes overcome common challenges with capping efficiency and dsRNA impurities in IVT manufacturing of mRNA required for vaccines and cell/gene therapeutics.Register Now
Discovering and developing life-changing treatments for patients is our focus. By tailoring biotherapeutic performance using novel protein and gene therapies, we are well-positioned to address unmet medical needs and find treatments for a wide range of diseases and disorders.Learn More
Highly specialized enzymes can address many challenges faced in DNA and RNA synthesis, NGS, and clinical diagnostics. Whether it’s yield, accuracy, or sample conditions, engineered enzymes can help provide better results.Learn More
Biocatalysis enabled by engineered enzymes can eliminate the use of hazardous reagents, remove wasteful steps, and reduce overall manufacturing cost for small molecule pharmaceuticals production. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.Learn More
At Codexis, we strive to innovate sustainable processes and products, and discover and develop effective therapeutics – all to create a brighter future.
These goals are grand but not beyond reach. Together with our business partners and loyal customers, we can make them a reality.